• +1-646-491-9876
    • +91-20-67278686

    Search

    Hepatitis B - Pipeline Review, H2 2016

    Hepatitis B - Pipeline Review, H2 2016

    • Report Code ID: RW0001499732
    • Category Pharmaceuticals
    • No. of Pages 389
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Hepatitis B - Pipeline Review, H2 2016

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Pipeline Review, H2 2016, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.

    Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 10, 24, 18, 3, 58, 33 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 7 and 6 molecules, respectively.Hepatitis B.

    Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents

    Introduction 7
    Hepatitis B Overview 8
    Therapeutics Development 9
    Hepatitis B - Therapeutics under Development by Companies 11
    Hepatitis B - Therapeutics under Investigation by Universities/Institutes 19
    Hepatitis B - Pipeline Products Glance 20
    Hepatitis B - Products under Development by Companies 24
    Hepatitis B - Products under Investigation by Universities/Institutes 33
    Hepatitis B - Companies Involved in Therapeutics Development 34
    Hepatitis B - Therapeutics Assessment 121
    Drug Profiles 133
    Hepatitis B - Dormant Projects 345
    Hepatitis B - Discontinued Products 357
    Hepatitis B - Product Development Milestones 358
    Appendix 369

    List of Tables

    Number of Products under Development for Hepatitis B, H2 2016 27
    Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2016 28
    Number of Products under Development by Companies, H2 2016 30
    Number of Products under Development by Companies, H2 2016 (Contd..1) 31
    Number of Products under Development by Companies, H2 2016 (Contd..2) 32
    Number of Products under Development by Companies, H2 2016 (Contd..3) 33
    Number of Products under Development by Companies, H2 2016 (Contd..4) 34
    Number of Products under Development by Companies, H2 2016 (Contd..5) 35
    Number of Products under Development by Companies, H2 2016 (Contd..6) 36
    Number of Products under Investigation by Universities/Institutes, H2 2016 37
    Comparative Analysis by Late Stage Development, H2 2016 38
    Comparative Analysis by Clinical Stage Development, H2 2016 39
    Comparative Analysis by Early Stage Development, H2 2016 40
    Comparative Analysis by Unknown Stage Development, H2 2016 41
    Products under Development by Companies, H2 2016 42
    Products under Development by Companies, H2 2016 (Contd..1) 43
    Products under Development by Companies, H2 2016 (Contd..2) 44
    Products under Development by Companies, H2 2016 (Contd..3) 45
    Products under Development by Companies, H2 2016 (Contd..4) 46
    Products under Development by Companies, H2 2016 (Contd..5) 47
    Products under Development by Companies, H2 2016 (Contd..6) 48
    Products under Development by Companies, H2 2016 (Contd..7) 49
    Products under Development by Companies, H2 2016 (Contd..8) 50
    Products under Investigation by Universities/Institutes, H2 2016 51
    Hepatitis B - Pipeline by Abivax SA, H2 2016 52
    Hepatitis B - Pipeline by AiCuris GmbH & Co KG, H2 2016 53
    Hepatitis B - Pipeline by AIMM Therapeutics BV, H2 2016 54
    Hepatitis B - Pipeline by Akshaya Bio Inc, H2 2016 55
    Hepatitis B - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 56
    Hepatitis B - Pipeline by AlphaMab Co., Ltd, H2 2016 57
    Hepatitis B - Pipeline by Altimmune Inc, H2 2016 58
    Hepatitis B - Pipeline by Altravax Inc, H2 2016 59
    Hepatitis B - Pipeline by Amarna Therapeutics BV, H2 2016 60
    Hepatitis B - Pipeline by Arbutus Biopharma Corp, H2 2016 61
    Hepatitis B - Pipeline by Arcturus Therapeutics Inc, H2 2016 62
    Hepatitis B - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 63
    Hepatitis B - Pipeline by Assembly Biosciences Inc, H2 2016 64
    Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016 65
    Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 66
    Hepatitis B - Pipeline by Benitec Biopharma Ltd, H2 2016 67
    Hepatitis B - Pipeline by Biogenomics Limited, H2 2016 68
    Hepatitis B - Pipeline by Biological E Ltd, H2 2016 69
    Hepatitis B - Pipeline by BioStar Pharmaceuticals Inc, H2 2016 70
    Hepatitis B - Pipeline by Bolder Biotechnology Inc, H2 2016 71
    Hepatitis B - Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2016 72
    Hepatitis B - Pipeline by Bukwang PharmCo Ltd, H2 2016 73
    Hepatitis B - Pipeline by CaroGen Corp, H2 2016 74
    Hepatitis B - Pipeline by Celltrion Inc, H2 2016 75
    Hepatitis B - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 76
    Hepatitis B - Pipeline by Chromis Therapeutics, Inc., H2 2016 77
    Hepatitis B - Pipeline by ChronTech Pharma AB, H2 2016 78
    Hepatitis B - Pipeline by Cocrystal Pharma Inc, H2 2016 79
    Hepatitis B - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 80
    Hepatitis B - Pipeline by CyTuVax BV, H2 2016 81
    Hepatitis B - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 82
    Hepatitis B - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 83
    Hepatitis B - Pipeline by Dynavax Technologies Corp, H2 2016 84
    Hepatitis B - Pipeline by Ensemble Therapeutics Corp, H2 2016 85
    Hepatitis B - Pipeline by eTheRNA Immunotherapies NV, H2 2016 86
    Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 87
    Hepatitis B - Pipeline by GeneCure LLC, H2 2016 88
    Hepatitis B - Pipeline by GeoVax Labs Inc, H2 2016 89
    Hepatitis B - Pipeline by Gilead Sciences Inc, H2 2016 90
    Hepatitis B - Pipeline by GlaxoSmithKline Plc, H2 2016 91
    Hepatitis B - Pipeline by Green Cross Corp, H2 2016 92
    Hepatitis B - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 93
    Hepatitis B - Pipeline by HEC Pharm Co., Ltd., H2 2016 94
    Hepatitis B - Pipeline by Humabs BioMed SA, H2 2016 95
    Hepatitis B - Pipeline by Huons Co Ltd, H2 2016 96
    Hepatitis B - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2016 97
    Hepatitis B - Pipeline by Immunotope Inc, H2 2016 98
    Hepatitis B - Pipeline by Indian Immunologicals Ltd, H2 2016 99
    Hepatitis B - Pipeline by Intellia Therapeutics Inc, H2 2016 100
    Hepatitis B - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 101
    Hepatitis B - Pipeline by ISA Pharmaceuticals BV, H2 2016 102
    Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016 103
    Hepatitis B - Pipeline by Johnson & Johnson, H2 2016 104
    Hepatitis B - Pipeline by Kineta Inc, H2 2016 105
    Hepatitis B - Pipeline by Lakewood-Amedex Inc, H2 2016 106
    Hepatitis B - Pipeline by Leukocare AG, H2 2016 107
    Hepatitis B - Pipeline by LG Life Science LTD, H2 2016 108
    Hepatitis B - Pipeline by Ligand Pharmaceuticals Inc, H2 2016 109
    Hepatitis B - Pipeline by Mucosis BV, H2 2016 110
    Hepatitis B - Pipeline by MultiCell Technologies Inc, H2 2016 111
    Hepatitis B - Pipeline by Oncolys BioPharma Inc, H2 2016 112
    Hepatitis B - Pipeline by Panacea Biotec Ltd, H2 2016 113
    Hepatitis B - Pipeline by Pfenex Inc, H2 2016 114
    Hepatitis B - Pipeline by PharmaEssentia Corp, H2 2016 115
    Hepatitis B - Pipeline by Poxel SA, H2 2016 116
    Hepatitis B - Pipeline by Profarma, H2 2016 117
    Hepatitis B - Pipeline by Profectus BioSciences Inc, H2 2016 118
    Hepatitis B - Pipeline by Redx Pharma Plc, H2 2016 119
    Hepatitis B - Pipeline by REPLICor Inc, H2 2016 120
    Hepatitis B - Pipeline by Rodos BioTarget GmbH, H2 2016 121
    Hepatitis B - Pipeline by Samjin Pharmaceutical Co Ltd, H2 2016 122
    Hepatitis B - Pipeline by Sanofi Pasteur SA, H2 2016 123
    Hepatitis B - Pipeline by Shantha Biotechnics Ltd, H2 2016 124
    Hepatitis B - Pipeline by Sinovac Biotech Ltd, H2 2016 125
    Hepatitis B - Pipeline by Spring Bank Pharmaceuticals Inc, H2 2016 126
    Hepatitis B - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H2 2016 127
    Hepatitis B - Pipeline by TCM Biotech International Corp, H2 2016 128
    Hepatitis B - Pipeline by TetraLogic Pharmaceuticals, H2 2016 129
    Hepatitis B - Pipeline by TGV-Laboratories, H2 2016 130
    Hepatitis B - Pipeline by Theravectys SA, H2 2016 131
    Hepatitis B - Pipeline by Tomegavax Inc, H2 2016 132
    Hepatitis B - Pipeline by Transgene SA, H2 2016 133
    Hepatitis B - Pipeline by Vaxine Pty Ltd, H2 2016 134
    Hepatitis B - Pipeline by VBI Vaccines Inc, H2 2016 135
    Hepatitis B - Pipeline by Viriom Ltd, H2 2016 136
    Hepatitis B - Pipeline by VLP Biotech Inc, H2 2016 137
    Hepatitis B - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 138
    Assessment by Monotherapy Products, H2 2016 139
    Assessment by Combination Products, H2 2016 140
    Number of Products by Stage and Target, H2 2016 142
    Number of Products by Stage and Mechanism of Action, H2 2016 145
    Number of Products by Stage and Route of Administration, H2 2016 148
    Number of Products by Stage and Molecule Type, H2 2016 150
    Hepatitis B - Dormant Projects, H2 2016 363
    Hepatitis B - Dormant Projects (Contd..1), H2 2016 364
    Hepatitis B - Dormant Projects (Contd..2), H2 2016 365
    Hepatitis B - Dormant Projects (Contd..3), H2 2016 366
    Hepatitis B - Dormant Projects (Contd..4), H2 2016 367
    Hepatitis B - Dormant Projects (Contd..5), H2 2016 368
    Hepatitis B - Dormant Projects (Contd..6), H2 2016 369
    Hepatitis B - Dormant Projects (Contd..7), H2 2016 370
    Hepatitis B - Dormant Projects (Contd..8), H2 2016 371
    Hepatitis B - Dormant Projects (Contd..9), H2 2016 372
    Hepatitis B - Dormant Projects (Contd..10), H2 2016 373
    Hepatitis B - Dormant Projects (Contd..11), H2 2016 374
    Hepatitis B - Discontinued Products, H2 2016 375

    List of Figures

    Number of Products under Development for Hepatitis B, H2 2016 27
    Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2016 28
    Number of Products under Development by Companies, H2 2016 29
    Number of Products under Investigation by Universities/Institutes, H2 2016 37
    Comparative Analysis by Late Stage Development, H2 2016 38
    Comparative Analysis by Clinical Stage Development, H2 2016 39
    Comparative Analysis by Early Stage Products, H2 2016 40
    Assessment by Monotherapy Products, H2 2016 139
    Assessment by Combination Products, H2 2016 140
    Number of Products by Top 10 Targets, H2 2016 141
    Number of Products by Stage and Top 10 Targets, H2 2016 141
    Number of Products by Top 10 Mechanism of Actions, H2 2016 144
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 144
    Number of Products by Routes of Administration, H2 2016 147
    Number of Products by Stage and Routes of Administration, H2 2016 147
    Number of Products by Top 10 Molecule Types, H2 2016 149
    Number of Products by Stage and Top 10 Molecule Types, H2 2016 149
    Abivax SA
    AiCuris GmbH & Co KG
    AIMM Therapeutics BV
    Akshaya Bio Inc
    Alnylam Pharmaceuticals Inc
    AlphaMab Co., Ltd
    Altimmune Inc
    Altravax Inc
    Amarna Therapeutics BV
    Arbutus Biopharma Corp
    Arcturus Therapeutics Inc
    Arrowhead Pharmaceuticals Inc
    Assembly Biosciences Inc
    Beijing Kawin Technology Share-Holding Co Ltd
    Beijing Minhai Biotechnology Co Ltd
    Benitec Biopharma Ltd
    Biogenomics Limited
    Biological E Ltd
    BioStar Pharmaceuticals Inc
    Bolder Biotechnology Inc
    BrightGene Bio-Medical Technology Co Ltd
    Bukwang PharmCo Ltd
    CaroGen Corp
    Celltrion Inc
    Chong Kun Dang Pharmaceutical Corp
    Chromis Therapeutics, Inc.
    ChronTech Pharma AB
    Cocrystal Pharma Inc
    ContraVir Pharmaceuticals Inc
    CyTuVax BV
    Dicerna Pharmaceuticals Inc
    Dong-A Socio Holdings Co Ltd
    Dynavax Technologies Corp
    Ensemble Therapeutics Corp
    eTheRNA Immunotherapies NV
    F. Hoffmann-La Roche Ltd
    GeneCure LLC
    GeoVax Labs Inc
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Green Cross Corp
    Hanmi Pharmaceuticals Co Ltd
    HEC Pharm Co., Ltd.
    Humabs BioMed SA
    Huons Co Ltd
    Ildong Pharmaceutical Co Ltd
    Immunotope Inc
    Indian Immunologicals Ltd
    Intellia Therapeutics Inc
    Ionis Pharmaceuticals Inc
    ISA Pharmaceuticals BV
    Jiangsu Hansoh Pharmaceutical Co Ltd
    Johnson & Johnson
    Kineta Inc
    Lakewood-Amedex Inc
    Leukocare AG
    LG Life Science LTD
    Ligand Pharmaceuticals Inc
    Mucosis BV
    MultiCell Technologies Inc
    Oncolys BioPharma Inc
    Panacea Biotec Ltd
    Pfenex Inc
    PharmaEssentia Corp
    Poxel SA
    Profarma
    Profectus BioSciences Inc
    Redx Pharma Plc
    REPLICor Inc
    Rodos BioTarget GmbH
    Samjin Pharmaceutical Co Ltd
    Sanofi Pasteur SA
    Shantha Biotechnics Ltd
    Sinovac Biotech Ltd
    Spring Bank Pharmaceuticals Inc
    Staidson (Beijing) Biopharmaceuticals Co., Ltd.
    TCM Biotech International Corp
    TetraLogic Pharmaceuticals
    TGV-Laboratories
    Theravectys SA
    Tomegavax Inc
    Transgene SA
    Vaxine Pty Ltd
    VBI Vaccines Inc
    Viriom Ltd
    VLP Biotech Inc
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//hepatitis-b-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hepatitis-b-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hepatitis-b-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments